ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC

BACKGROUND: ROS1 fusions are driver molecular alterations in 1–2% of non-small cell lung cancers (NSCLCs). Several tyrosine kinase inhibitors (TKIs) have shown high efficacy in patients whose tumors harbour a ROS1 fusion. However, the limited availability of preclinical models of ROS1-positive NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruzzi, Francesca, Angelicola, Stefania, Landuzzi, Lorena, Nironi, Elena, Semprini, Maria Sofia, Scalambra, Laura, Altimari, Annalisa, Gruppioni, Elisa, Fiorentino, Michelangelo, Giunchi, Francesca, Ferracin, Manuela, Astolfi, Annalisa, Indio, Valentina, Ardizzoni, Andrea, Gelsomino, Francesco, Nanni, Patrizia, Lollini, Pier-Luigi, Palladini, Arianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742620/
https://www.ncbi.nlm.nih.gov/pubmed/36519016
http://dx.doi.org/10.21037/tlcr-22-163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742620/
https://www.ncbi.nlm.nih.gov/pubmed/36519016
http://dx.doi.org/10.21037/tlcr-22-163

Ejemplares similares